Ginkgo Biloba - Pain management for peripheral arterial occlusive disease

Posted by Mikiko Murakami on May 4th, 2007
2007
May 4

Patients with peripheral arterial occlusive disease, Frontaine’s stage II, received a standard dose (120mg) or a high dose (240mg) of Egb 761. Pain-free walking distance was significantly improved for both groups but significantly more improved with the higher dose. [Schwizer & Hautmann (1999)]

Reference:
Freedman, Lynda W, PhD et al. Best Practices in Compelmentary and Alternative Medicine. Maryland: Aspen Publishers, 2001.

Ginkgo Biloba has significant effect on ventricular myosin leakage and successful in limiting oxidative stress in response to cardiovascular surgery

Posted by Mikiko Murakami on Mar 2nd, 2007
2007
Mar 2

Patients undergoing aortic valve replacement were assessed to determine if reperfusion injury (induced lipid peroxidation, ascorbate depletion, tissue necrosis, and cardia damage) is reduced by orally administering Ginkgo biloba for 5 days before cardiopulmonary bypass surgery. Plasmy samples were taken from peripheral circulation and the coronary sinus before incision, during ischemia, within the fist 30 minutes after unclamping, and up to 8 days after surgery. Upon aortic unclamping, ginkgo inhibited the transcardiac release of thiobarcituric acid-reactive species and attenuated the early decrease in dimethylsulfoxide/ascorbyl free radical levels. Leakage of myoglobin was significantly delayed, and gingko had significant effect on ventricular myosin leakage. Ginkgo was successful in limiting oxidative stress in response to cardiovascular surgery. [Pietri et al. (1997)]

Reference:
Freedman, Lynda W, PhD et al. Best Practices in Compelmentary and Alternative Medicine. Maryland: Aspen Publishers, 2001.